94749-70-9

Basic information

• Product Name: Benzoic acid, 5-(2R)-oxiranyl-2-(phenylmethoxy)-, methyl ester
• CAS NO: 94749-70-9
• Molecular Formula: C17H16O4
• Molecular Weight: 284.312
• Mol File: 94749-70-9.mol

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 5-(2R)-oxiranyl-2-(phenylmethoxy)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 5-(2R)-oxiranyl-2-(phenylmethoxy)-, methyl ester(94749-70-9)
• EPA Substance Registry System: Benzoic acid, 5-(2R)-oxiranyl-2-(phenylmethoxy)-, methyl ester(94749-70-9)

Safety Data

• Hazardous Substances Data: 94749-70-9(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 27475-09-8 5-acetyl-2-benzyloxybenzoic acid methyl ester 
• 16475-90-4 estere metilico dell'acido 5-acetilsalicilico 
• 27475-14-5 2-benzyloxy-5-(2-bromoacetyl)benzoic acid methyl ester 
• 160889-18-9 2-benzyloxy-5-(2-bromo-1(R)-hydroxyethyl)benzoic acid methyl ester 

Downstream Products

• 960398-43-0 4-(2-(4-(4-(4-aminobutyl)phenyl)butylamino)-1-(R)-hydroxyethyl)-2-hydroxymethylphenol 
• 960398-42-9 (4-(4-(4-(2-(4-benzyloxy-3-hydroxymethylphenyl)-2-(R)-hydroxyethylamino)butyl)phenyl)butyl)carbamic acid benzyl ester 
• 960398-45-2 (4-(4-(4-(bis-(2-(4-hydroxy-3-hydroxymethylphenyl)-2-(R)-hydroxyethyl)amino)butyl)phenyl)butyl)amine 
• 960398-44-1 (4-(4-(4-(bis-(2-(4-benzyloxy-3-hydroxymethylphenyl)-2-(R)-hydroxyethyl)amino)butyl)phenyl)butyl)carbamic acid benzyl ester 
• 321708-89-8 C₄₇H₄₈N₂O₅ 
• 1355183-85-5 C₄₇H₄₈N₂O₅ 
• 135271-47-5 (R)-(-)-salmeterol 
• 960398-41-8 2-benzyloxy-5-(2-(4-(4-(4-benzyloxycarbonylaminobutyl)phenyl)butylamino)-1-(R)-hydroxyethyl)benzoic acid methyl ester 
• 960398-79-2 C₅₆H₆₂N₂O₁₀ 
• 160889-19-0 2-Benzyloxy-5-((R)-2-{benzyl-[6-(4-phenyl-butoxy)-hexyl]-amino}-1-hydroxy-ethyl)-benzoic acid methyl ester 
• 1055276-51-1 C₄₆H₄₆N₂O₅ 
• 1055276-55-5 C₄₅H₄₄N₂O₅ 
• 1055276-54-4 C₄₀H₄₂N₂O₅ 

Relevant articles and documents

PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

Enantioselective synthesis of salmeterol via asymmetric borane reduction

Enantioselective syntheses of both enantiomers of salmeterol are accomplished using asymmetric borane reductions with chiral oxazaborolidines as catalysts.